IVDs, LDTs, companion diagnostics — FDA & EU IVDR.
On May 6, 2024 the FDA released a final rule which added the words "including when the manufacturer of such products is a laboratory" to the definition of "in vitro diagnostic product" at 21 CFR 809.3 (a). The FDA revised this final rule on March 31, 2025, with a U.S. District Court vacating the same and returning the wording back to what was present in the regulation before its effective date, on September 19, 2025.Most companies still have relaxed requirements against FDA and EU IVDR, both of which redefined the diagnostic industry standards, most laboratories do not currently comply with these regulations.
We can create a Compliance strategy for FDA and EU IVDR regarding IVDs, LDTs, Next Generation Sequencing based Assays, Companion Diagnostics and Software-Only IVDs.
IVDs, LDTs, companion diagnostics — FDA & EU IVDR.
FDA + EU IVDR strategy for IVDs, LDTs, NGS-based assays, companion diagnostics and software-only IVDs.
Risk-based regulatory and quality strategy for diagnostic platforms, IVDs and companion-diagnostic programs across development, clinical use and market access.”
Diagnostics
Tell us about your program — we typically respond within one business day.
Book a free 30-min consult
